DRKS00031641CompletedNot Applicable
Cell-free DNA as a prognostic biomarker in patients with COVID-19 disease
niversitätsmedizin Mainz0 sites72 target enrollmentStarted: July 13, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 72
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •COVID-19 disease
Exclusion Criteria
- •- pregnancy
- •- breast feeding women
- •- Blood sample taken too late
- •- medication (Remicade, Tofacitinib)
Investigators
Similar Trials
Completed
Not Applicable
Cellfree DNA as a prognostic biomarker in ICU patients suffering from COVID-19 or sepsisCOVID-19, sepsisA41.9Sepsis, unspecifiedDRKS00025222Klinik für Anästhesiologie der Universitätsmedizin Mainz64
Recruiting
Not Applicable
Biomarker study using cell free DNA in patients with gastric canceradvanced gastric cancerJPRN-UMIN000014209Kindai University Faculty of Medicine
Recruiting
Not Applicable
Biomarker study using cell free DNA in patients with colorectal canceradvanced colorectal cancerJPRN-UMIN000017966Kindai University Faculty of Medicine160
Recruiting
Not Applicable
Biomarker study using cell-free DNA from patients with advanced breast canceradvanced breast cancerJPRN-UMIN000012881Kinki University Faculty of Medicine100
Completed
Not Applicable
cfDNA as a predictive marker for the prognosis of severe courses in patients with influenza-like symptoms with and without SARS-CoV-2 infections in General Practice: A prospective cohort study.J06.9U07.1Acute upper respiratory infection, unspecifiedCOVID-19, virus identifiedDRKS00024722Institut für Allgemeinmedizin, Universitätsklinikum Essen74